 |
autologous human peripheral blood mononuclear cells incubated ex vivo with protein TBX-4000 (Tat-MYC) |
|---|---|
| Trade Name | |
| Orphan Indication | Malignant melanoma Stages IIb to IV |
| USA Market Approval | USA |
| USA Designation Date | 2017-10-16 00:00:00 |
| Sponsor | Taiga Biotechnologies, Inc.;12635 Montview Boulevard, Fitzsimmons BBioscience Park Center;Aurora, Colorado, 80045 |
